Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Companyâ€™s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Employees

1,402

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
13/03/26	71.19 $	-1.59%	1,972,137
12/03/26	72.34 $	-3.28%	2,461,797
11/03/26	74.79 $	-1.15%	1,895,367
10/03/26	75.66 $	+0.40%	2,785,714
09/03/26	75.36 $	+1.78%	3,215,157

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

71.19USD

Average target price

93.90USD

Spread / Average Target

+31.90%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 00:00:00 14/03/2026 +04			5-day change	1st Jan Change
71.19 ^USD	-1.59%		-3.85%	-10.01%

03-12	Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial Program	CI
03-11	Ionis Pharmaceuticals, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:30 PM

Capitalization	11.76B 10.28B 9.29B 8.88B 16.16B 1,088B 16.8B 111B 43.97B 520B 44.13B 43.2B 1,877B	P/E ratio 2026 *	-17.6x	P/E ratio 2027 *	-46.2x
Enterprise value	11.35B 9.92B 8.96B 8.57B 15.59B 1,050B 16.21B 107B 42.43B 502B 42.59B 41.69B 1,811B	EV / Sales 2026 *	13.7x	EV / Sales 2027 *	8.14x
Free-Float	99.23%	Yield 2026 *	-	Yield 2027 *	-

03-12	Biogen Inc. Presents Additional Salanersen Data and Debuts Phase 3 Clinical Trial Program	CI
03-11	Ionis Pharmaceuticals, Inc. Presents at Barclays 28th Annual Global Healthcare Conference, Mar-11-2026 01:30 PM
03-10	Ionis Pharmaceuticals, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 03:40 PM
03-09	Ionis Pharmaceuticals, Inc. Announces Board Changes, Effective June 4, 2026	CI
03-06	Ionis Pharmaceuticals Insider Sold Shares Worth $1,696,181, According to a Recent SEC Filing	MT
03-06	Ionis Pharmaceuticals Insider Sold Shares Worth $4,354,428, According to a Recent SEC Filing	MT
03-05	Biogen Inc Announces to Present New Data and Updates from Its Spinal Muscle Atrophy Research Programs	CI
03-02	Ionis Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 10:30 AM
02-27	Ionis Pharmaceuticals, Inc. Announces to Present New Data Supporting Dawnzera (Donidalorsen) in Hereditary Angioedema At 2026 Aaaai Annual Meeting	CI
02-27	Olezarsen sNDA accepted by the FDA for Priority Review	RE
02-26	Ionis Pharmaceuticals, Inc. Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference, Feb-26-2026 12:00 PM
02-26	Ionis Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Accepts for Priority Review the Supplemental New Drug Application for Olezarsen for Severe Hypertriglyceridemia	CI
02-26	GSK moves towards clearance of two new drugs in China and Japan	AN

12-17	RBC Raises Price Target on Ionis Pharmaceuticals to $95 From $82, Keeps Outperform Rating	MT
11-12	Arrowhead Has Large Market Opportunity With Severe Hypertriglyceridemia Treatment, Morgan Stanley Says	MT
30/10/25	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
28/10/25	Intellia Therapeutics' Liver Toxicity Claim in Phase 3 Trials 'Unconvincing,' RBC Says	MT
16/10/25	Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating	MT

Ionis Pharmaceuticals, Inc. Stock

Equities

IONS

US4622221004

Biotechnology & Medical Research

Valuation: Ionis Pharmaceuticals, Inc.

Chart: Ionis Pharmaceuticals, Inc.

Latest news: Ionis Pharmaceuticals, Inc.

Last Transcript: Ionis Pharmaceuticals, Inc.

Analysts' recommendations: Ionis Pharmaceuticals, Inc.

Press Releases: Ionis Pharmaceuticals, Inc.

News in other languages: Ionis Pharmaceuticals, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Ionis Pharmaceuticals, Inc.

ETFs: Ionis Pharmaceuticals, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

03-09	Ionis announces changes to Board of Directors	BU
03-02	Ionis to present new data supporting DAWNZERA in hereditary angioedema at 2026 AAAAI Annual Meeting	AQ
02-27	Ionis Pharmaceuticals : Additional Benefit of Switching to Donidalorsen for Patients with Hereditary Angioedema Having Breakthrough Attacks Findings from the OASISplus Study	PU
02-27	Ionis Pharmaceuticals : Patient Reported Disease Control, Work Productivity, and Activity Impairment in Hereditary Angioedema Insights from OASIS HAE	PU
02-27	Ionis Pharmaceuticals : Predictors of Disease Control, Attack Rate, and Quality of Life in HAE An Exploratory Analysis	PU

01-07	Tratamiento contra hepatitis B crónica de GSK se muestra prometedor en estudios clave
30/10/25	Wall Street : Toujours debout, mais légèrement chancelant
24/10/25	BB Biotech profitiert von Erfolgen im Portfolio
08/10/25	Wall Street : En attente de signaux
03/09/25	Wall Street : Antitrust en recul, rendements en hausse

1 day	-1.59%
1 week	-3.85%
Current month	-12.27%
1 month	-11.67%
3 months	-11.92%
6 months	+12.71%
Current year	-10.01%

1 week	70.42	77.03
1 month	70.42	85.47
Current year	70.42	86.74
1 year	23.95	86.74
3 years	23.95	86.74
5 years	23.95	86.74
10 years	19.59	86.74

Manager	Title	Age	Since
Brett Monia CEO	Chief Executive Officer	64	01/01/2020
D. Walke IRC	Investor Relations Contact	60	01/07/2012
Elizabeth Hougen DFI	Director of Finance/CFO	64	01/05/2000

Director	Title	Age	Since
B. Parshall BRD	Director/Board Member	71	01/09/2000
Joseph Wender BRD	Director/Board Member	81	01/01/1994
Joseph Klein BRD	Director/Board Member	64	13/12/2005

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
IONIS PHARMACEUTICALS, INC.	-1.59%	-3.85%	+115.99%	+110.87%	11.76B
LONZA GROUP AG	-0.72%	-4.60%	-12.29%	-8.00%	42.78B
BEONE MEDICINES AG	-0.44%	-5.67%	+9.59%	+22.80%	31.5B
CELLTRION, INC.	-0.24%	-3.29%	+14.84%	+48.71%	29.99B
IQVIA HOLDINGS INC.	+1.10%	-5.60%	-11.05%	-17.93%	27.65B
REVOLUTION MEDICINES, INC.	-0.22%	-3.60%	+142.48%	+304.69%	18.8B
ASCENDIS PHARMA A/S	-1.32%	-6.10%	+47.72%	+106.64%	13.87B
MEDPACE HOLDINGS, INC.	+1.48%	-4.29%	+38.61%	+148.23%	12.78B
EUROFINS SCIENTIFIC SE	-0.29%	-4.80%	+24.93%	+0.10%	12.39B
REGENCELL BIOSCIENCE HOLDINGS LIMITED	-3.21%	-0.51%	+6,894.88%	+3,230.94%	11.49B
Average	-0.55%	-3.83%	+726.57%	+394.71%	21.3B
Weighted average by Cap.	-0.39%	-3.88%	+397.29%	+229.40%

	2026 *	2027 *
Net sales	828M 723M 654M 625M 1.14B 76.56B 1.18B 7.81B 3.09B 36.57B 3.11B 3.04B 132B	1.36B 1.19B 1.08B 1.03B 1.87B 126B 1.95B 12.86B 5.1B 60.26B 5.12B 5.01B 218B
Net income	-669M -585M -528M -505M -919M -61.88B -956M -6.31B -2.5B -29.56B -2.51B -2.46B -107B	-267M -233M -211M -201M -366M -24.66B -381M -2.52B -997M -11.78B -1B -980M -42.56B
Net Debt	-411M -359M -325M -310M -565M -38.01B -587M -3.88B -1.54B -18.16B -1.54B -1.51B -65.59B	-663M -579M -523M -501M -911M -61.29B -946M -6.25B -2.48B -29.28B -2.49B -2.43B -106B